Latus Bio Inc. is developing a new gene therapy, LTS-101, for the treatment of neuronal ceroid lipofuscinosis type2 (CLN2), a form of Batten disease characterized by deficiency in the tripeptidyl ...
The National Institute for Health and Care Excellence (NICE) has rejected recommending cerliponase alfa (Brineura, BioMarin) for treating a rare form of Batten disease known as neuronal ceroid ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果